Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics

Annals of the New York Academy of Sciences

Volumn 1346, Issue 1, 2015, Pages 63-70

  Halim, Abdel Baset ^a  

^a Celldex Therapeutics Inc   (United Kingdom)

Author keywords

Analytical; Biomarkers; Challenges; Companion diagnostics; Personalized medicine; Preanalytical

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; REAGENT; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL LABORATORY; COMPANION DIAGNOSTICS; DIAGNOSTIC TEST; DRUG INDUSTRY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE MUTATION; HUMAN; LABORATORY TEST; MEDICAL STAFF; METHODOLOGY; MOLECULAR DIAGNOSTICS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRODUCTIVITY; PUBLICATION; QUALITY CONTROL; REIMBURSEMENT; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; DIAGNOSTIC PROCEDURE; DRUG DEVELOPMENT; ECONOMICS; LABORATORY DIAGNOSIS; MOLECULAR DIAGNOSIS; ORGANIZATION AND MANAGEMENT; PRESERVATION; PROCEDURES; REPRODUCIBILITY; STANDARDS;

BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; DRUG DISCOVERY; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; PRESERVATION, BIOLOGICAL; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING;

EID: 84941794352     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12707     Document Type: Article

References (28)

1. Accenture. 2007. Achieving high performance in pharmaceuticals reversing the R&D productivity decline. Cited July 5, 2014. http://www.accenture.com/Microsites/rdtransformation/Documents/PDFs/Accenture_Achieving_High_Performance:in_Pharmaceuticals.pdf.
2. Pammolli, F., L. Magazzini & M. Riccaboni. 2011. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10: 428-438.
3. Scannell, J.W., A. Blanckley, A.H. Boldon, et al. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11: 191-200.
4. Powers, M. 2014. Tufts CSDD study; the cost to develop a new drug balloons up to $2.6B. Bioworld Today 25: 1, 3.
5. Halim, A.-B. 2011. "Biomarkers in drug development: a useful tool but discrepant results may have a major impact." In Drug Discovery and Development-Present and Future. I.M. Kapetanovic, Ed.: 401-424. Croatia: InTech.
6. Halim, A.-B. 2014. The biggest challenges currently facing companion diagnostic advancement. Expert Rev. Mol. Diagn. 14: 27-35.
7. Naylor, S. & T. Cole. 2010. Overview of companion diagnostics in the pharmaceutical industry. Drug Discovery World Spring. Cited May 20, 2013. http://www.ddw-online.com/personalised-medicine/p92845-overview-of-companion-diagnostics-in-the-pharmaceutical-industry.spring-10.html.
8. Voight, B.F., G.M. Peloso, M. Orho-Melander, et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet 380: 572-580.
9. Harrison, S.C., M.V. Holmes & S.E. Humphries. 2012. Mendelian randomization, lipids, and cardiovascular disease. Lancet 380: 543-545.
10. Gerlinger, M., A.J. Rowan, S. Horswell, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366: 883-892.
11. Winter, P. 2014. Hurdles still need to be overcome to further personalized medicine. BioWorld 25: 1, 8.
12. Bonini, P., M. Plebani, F. Ceriotti, et al. 2001. Errors in laboratory medicine. Clin. Chem. 48: 691-698.
13. Press, M.F., G. Hung, W. Godolphinet, et al. 1994. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54: 2771-2777.
14. Thomson, T.A., M.M., Hayes, J.J. Spinelli, et al. 2001. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod. Pathol. 14: 1079-1086.
15. Wolff, A.C., M. Elizabeth, H. Hammond, et al. 2007. American society of clinical oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 131: 18-43.
16. Hammond, M.E.H., D.F. Hayes, M. Dowsett, et al. 2010. American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28: 2784-2795.
17. Halim, A.-B. 2009. Impact of discrepant results from clinical laboratories on patients and pharmaceutical trials: evidence from proficiency testing results. Biomarkers Med. 3: 231-238.
18. Halim, A.-B. 2011. Discrepant results from laboratories impact patients receiving heparin or antithrombin therapy. Biomarkers Med. 5: 211-218.
19. Medscape. 2011. Molecular testing has a long way to go. National Comprehensive Cancer Network (NCCN) 16th Annual Conference. Cited May 20, 2013. http://www.medscape.com/viewarticle/739507.
20. Halim, A.-B. 2013. Proficiency testing for monitoring global laboratory performance and identifying discordance. Lab. Med. 44: e19-30.
21. DAKO. 2010. HercepTest for gastric cancer, summary of safety and effectiveness (SSED). Cited May 20, 2014. http://www.accessdata.fda.gov/cdrh_docs/pdf/P980018S010b.pdf.
22. Dako. 2015. HercepTest kit insert. Cited May 20, 2014. http://www.dako.com/28633_04may10_herceptest_brochure-9086.pdf.
23. Roche. 2012. FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer. June 11 2012. Cited May 20, 2014. http://www.roche.com/media/media_releases/med-cor-2012-06-11.htm.
24. Colombino, M., M. Capone & A. Lissia. 2012. ABRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30: 2522-2529.
25. Ascierto, P.A., J.M. Kirkwood, J.-J. Grob, et al. 2012. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10: 85.
26. Mayo Clinic. 2012. HER2-positive breast cancer: What is it? Cited October 14, 2014. http://www.mayoclinic.org/breast-cancer/expert-answers/faq-20058066.
27. Izarzugaza, Y., M. Domine & F. Rojo, et al. 2012. Prevalence of EGFR mutations in non-small cell lung cancer (NSCLC) smoker patients [Abstract]. J. Clin. Oncol. 30(Suppl.): e21015.
28. Bang, Y.-J. 2011. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther. Adv. Med. Oncol. 3: 279-291.